| Document |
Document Title |
|
WO/2007/107557A1 |
A process for preparing N,N-dimethylaminoethoxyethanol (DMAEE), wherein a) dimethylamine and ethylene oxide are reacted, b) the resulting product mixture is separated by distillation from N,N-dimethylethanol-amine and DMAEE to obtain a D...
|
|
WO/2007/104361A1 |
The present invention relates to organic nanofibers that can be produced from organic compounds having a core according to formula (I), wherein X and/or Y are C or N and n is 2 to 4 by self-organized growth on a solid substrate upon depo...
|
|
WO/2007/105982A1 |
The invention relates to novel N-methyl-para-ethoxyaniline, N,N-dimethyl-para-ethoxyaniline and N-methyl-N-acetyl-para-ethoxyaniline agents exhibiting a high antiknock activity, to para-ethoxyaniline, N-acetyl-para-ethoxyaniline, individ...
|
|
WO/2007/101527A1 |
A personal care composition is provided which includes a trihydroxy and quaternary ammonium substituted dipropyl ether. The substituted dipropyl ether functions as a humectant when applied to skin to moisturize both in high and low relat...
|
|
WO/2007/099894A1 |
An object is to provide a method for production of an industrially useful amine derivative safely and with high efficiency by employing a deprotecting technique which is applicable to any protected amine derivative for general purposes. ...
|
|
WO/2007/095756A1 |
This application relates to a new class of butylamine compounds useful as balanced serotonin/dopamine uptake inhibitors for treating a disease or condition for which inhibition of both serotonin and dopamine reuptake is beneficial, for e...
|
|
WO/2007/086883A2 |
The present invention relates to novel cationic lipids, transfection agents, microparticles, nanoparticles, and short interfering nucleic acid (siNA) molecules. The invention also features compositions, and methods of use for the study, ...
|
|
WO/2007/086881A2 |
The present invention relates to novel cationic lipids, transfection agents, microparticles, nanoparticles, and short interfering nucleic acid (siNA) molecules. The invention also features compositions, and methods of use for the study, ...
|
|
WO/2007/077140A1 |
The present invention relates to derivatives of tert-butoxy-norephedrine and/or -ephedrine and also to processes for their preparation. The invention additionally relates to processes for preparing 4-hydroxy-norephedrine, especially 4-hy...
|
|
WO/2007/074047A1 |
Method for producing the O-alkylated aminoalcohols of formula (I) by reacting N-unsubstituted or N-monosubstituted aminoalcoholate salts with alkyl halides, the aminoalcoholate salts being formed by alcoholates.
|
|
WO/2007/074046A2 |
Method for producing O-alkylated aminoalcohols by reacting N-unsubstituted or N-monosubstituted aminoalcoholates with alkyl halides, the aminoalcoholates being formed by means of alkali hydroxides or alkaline earth hydroxides.
|
|
WO/2007/071344A2 |
The invention relates to m-phenylenediamine derivatives of formula (I) and agents for dyeing keratin fibres, especially human hair, which contain as a coupling constituent at least one m-phenylenediamine derivative of formula (I) in a co...
|
|
WO/2007/073562A2 |
The present invention provides a metal chelator and methods that facilitate binding, detecting, monitoring and quantitating of heavy metal ions in a sample. This metal chelating moiety has the following formula (I).
|
|
WO/2007/068929A1 |
Compounds of formula (I) have muscarinic M3 receptor modulating activity; formula (I) wherein R1 is C1-C6-alkyl or a hydrogen atom; and R2 is a hydrogen atom or a group -R5, or a group, -Z-Y-R5, or a group -Z-NR9R10, or a group -Z-N(R9)C...
|
|
WO/2007/068324A1 |
The present invention discloses a process for the preparation of atomoxetine hydrochloride in a pure crystalline form, characterised by an XRPD spectrum as in (Fig 1). It is also object of the present invention to provide methods to obta...
|
|
WO/2007/069277A2 |
A process for preparing venlafaxine hydrochloride and also a process for preparing l-[2-amino- l-(4-methoxy phenyl)ethyl]cyclohexanol hydrochloride, an intermediate of venlafaxine hydrochloride are disclosed. p-Methoxy phenyl acetonitril...
|
|
WO/2007/069712A1 |
Disclosed is a novel amine compound represented by the general formula (I) below, a pharmaceutically acceptable acid addition salt of the compound, or a hydrate or solvate of the compound or the salt, which is excellent in an immunosuppr...
|
|
WO/2007/067501A1 |
A process for the enantio selective synthesis of an (S)- or (R)- l-[2- dimethylamino)-l-(methoxyphenyl)ethyl]cyclohexanol and analogues or salt thereof are described. The method involves the steps of (a) reacting an (S) or (R) 4- benzylo...
|
|
WO/2007/064697A1 |
Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disor...
|
|
WO/2007/062119A1 |
Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generali...
|
|
WO/2007/055180A1 |
Disclosed is a method for producing an optically active trans-2-aminocyclohexanol represented by the general formula (2) below or a protonic acid salt thereof. The method is characterized in that an optically active trans-2-benzylaminocy...
|
|
WO/2007/053755A1 |
Disclosed is a process for preparing substituted anisidines of formula I starting from substituted cyclic hydroxy-ketones II via aromatization through a substituted oxime intermediate IV in which R is C1-C6 alkyl or halogen, and Alk is C...
|
|
WO/2007/051576A1 |
Compounds of the formula (II) can be hydrogenated to the corresponding butane derivatives in the presence of homogeneous catalysts comprising metal salts or complexes containing metals from the group consisting of Rh, Ir and Ru and prefe...
|
|
WO/2007/051198A2 |
Photoactivatable prepolymers and methods of use thereof are disclosed for microencapsulation of a substantially water-insoluble material within a nonporous shell. As provided herein, the microencapsulated material is released with no mor...
|
|
WO/2007/047972A2 |
The invention encompasses processes for the preparation of highly pure venlafaxine hydrochloride, l-[2-dimethylamino-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride as well as intermediates thereof.
|
|
WO/2007/045857A1 |
The present invention relates to processes for the preparation of 4- hydroxy-α' -[[[6-(4-phenylbutoxy)hexyl]amino]methyl]- 1,3-benzenedimethanol 1-hydroxy-2-naphthoate (salmeterol xinafoate) (Formula (12a)), the preparation of 4-hydroxy...
|
|
WO/2007/039125A2 |
The invention provides an optically active form of the compound of formula (I), or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or ...
|
|
WO/2007/036781A1 |
The present invention relates to a compound of the formula (I) wherein R1 is hydrogen or C1-C6 alkyl; X and Y are independently selected from the group consisting of fluoro, chloro and bromo; its enantiomers, racemate and mixtures of ena...
|
|
WO/2007/036712A1 |
The invention provides ionic liquids and processes for their preparation. The liquids may either comprise a cation of the formula (I); N+HR1R2R3 (I) wherein R1 is a group -R4-O-R5; R2 and R3 are each independently either hydrogen or hydr...
|
|
WO/2007/036496A1 |
A method for preparing aminodiglycol (ADG) and morpholine by reaction of diethyleneglycol (DEG) with ammonia in the presence of a transition metal heterogeneous catalyst is characterised in that the catalytically active mass of the catal...
|
|
WO/2007/034924A1 |
Disclosed is a metallo-β-lactamase inhibitor which can inactivate a β-lactam antibiotic and recover the anti-bacterial activity of the β-lactam antibiotic. A maleic acid derivative having a structure of the general formula (I) has an ...
|
|
WO/2007/030587A1 |
The present invention provides improved processes for the preparation of atomoxetine hydrochloride under reaction conditions that improve reaction yields and facilitate commercial synthesis, m particular, the invention is directed to the...
|
|
WO/2007/025709A2 |
The invention relates to novel diamines of the formula (I) in which all variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments ...
|
|
WO/2007/027651A2 |
The present invention relates to compounds, which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, metabolic syndrome , hyperinsul...
|
|
WO/2007/026513A1 |
Disclosed is a fluoroether compound having a terminal alkylamino group represented by the following general formula: RfO[CF(CF3)CF2O]mCF(CF3)(CH2)nNR1R2 (wherein Rf represents a perfluoro lower alkyl group, R1 represents an alkyl group h...
|
|
WO/2007/020986A1 |
Disclosed is a substituted pyrazolecarboxylic acid anilide derivative represented by the general formula (I) below or a salt thereof, which has excellent effects as a pesticide or acaricide for agricultural and horticultural use. (I) (In...
|
|
WO/2007/017544A2 |
The invention relates to a method of obtaining 3,3-diphenylpropylamines (I), wherein R1 is H, alkyl, haloalkyl or alkoxyalkyl, R2 is alkyl, alkoxy, halogen, NO2, CN, CHO, which may be free or protected, CH2OH or COOR6, and R3 and R4 are ...
|
|
WO/2007/017267A2 |
Compounds of formula (I): are inhibitors of bacterial phenylalanyl t-RNA synthetase and are of use in treating bacterial infections.
|
|
WO/2007/014973A2 |
The invention relates to a method of obtaining phenyl carbamates (I), wherein R1 is lower alkyl C1-C5 or benzyl and R2 is methyl, ethyl or propyl, consisting in reacting L-(S)-3-[(1-methylamino)ethyl]phenol, in the presence of a base, wi...
|
|
WO/2007/015002A2 |
The crystalline form IV of a compound of formula (I) is characterised by the X diffraction diagram thereof on a powder.
|
|
WO/2007/010082A1 |
The invention relates to the use of copper-catalyzed nucleophilic aromatic substitution reaction for preparing 3-aryloxy-3-arylpropylamines and more specifically to a method of preparing certain 3-aryloxy-3-arylpropylamines and the pharm...
|
|
WO/2007/010350A1 |
This invention is directed to a method of synthesizing compounds of Formula (I) and to intermediates useful in the synthesis of compounds of Formula (I): wherein X, Y, R1, R2, R3, and R4 are as defined herein above.
|
|
WO/2007/006132A1 |
Provided is an efficient method for the preparation of 3-aryloxy-3- arylpropylamines, their optical stereoisomers, and pharmaceutically acceptable salts thereof. The process allows for the isolation of 3-aryloxy-3- arylpropylamines in hi...
|
|
WO/2007/005583A1 |
The present invention provides methods for preparing TLR-4 receptor agonist E6020 formula(I): and stereoisomers thereof, which compounds are useful as an immunological adjuvants when co-administered with antigens such as vaccines for bac...
|
|
WO/2007/005643A2 |
The present invention relates to a non-radioactive, heavy-atom isotopologue of Compound 1 containing one or more deuterium in place of a hydrogen covalently bound to carbon. The Compound 1 isotopologues of the invention are inhibitors of...
|
|
WO/2007/000334A1 |
A compound of formula (I), wherein A represents 2,3-dihydro-1-benzofuran-7-yl, 5-fluoro-2-methoxy-phenyl or 5-fluoro-2-hydroxy-phenyl; and R1 and R2 each independently represent hydrogen, fluorine or chlorine; or a physiologically functi...
|
|
WO/2006/136063A1 |
The present invention discloses a new type of aporphine or secoaporphine compounds, a process for producing the same, and a pharmaceutical composition comprising the said compound which is used for preventing or treating diabetes. The sa...
|
|
WO/2006/136682A2 |
The invention relates to preparing linear or C8 and more fatty chain branched triamines and ether diamines obtainable by hydrogenating aliphatic dinitrile derivatives, to the use of the thus obtainable products and, more specifically, to...
|
|
WO/2006/133652A1 |
Compounds of the general formula (I), optical isomers, pharmaceutically acceptable salts, preparation process and uses thereof in which R1, R2, R3 and R4 are as defined in specification are disclosed. Such compounds can be optical isomer...
|
|
WO/2006/135694A2 |
Disclosed herein are novel aromatic-containing compounds and methods for using various aromatic-containing compounds for treatment and prevention of diseases and disorders related to the Urotensin II receptor.
|
